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Abstract
Background: The suppressor of cytokine signalling 3 (SOCS3) provides a link between cytokine action and their negative
consequences on insulin signalling. Thus SOCS3 is a potential candidate gene for type 2 diabetes (T2DM).
Methodology/Principal Findings: Based on HapMap we identified the polymorphism A+930RG (rs4969168) as a haplotype
tagging SNP (htSNP) sufficiently covering the genetic variation of the whole gene. We therefore examined the association
between rs4969168 within SOCS3 and T2DM in three independent study populations; one prospective case-cohort study
and two cross-sectional study populations. Due to the low frequency of individuals being homozygous for the
polymorphism a dominant model of inheritance was assumed. The case-cohort study with 2,957 individuals (764 of them
with incident T2DM) showed no effect of the polymorphism on diabetes risk (hazard ratio (95%CI): 0.86 (0.66–1.13); p=0.3).
Within the MeSyBePo-study population 325 subjects had T2DM from a total of 1,897 individuals, while the second cross-
sectional cohort included 851 cases of T2DM within a total of 1653 subjects. According to the results in the prospective
study, no association with T2DM was found (odds ratio (95%CI): 0.78 (0.54–1.12) for MesyBepo and 1.13 (0.90–1.42) for the
Leipzig study population). There was also no association with metabolic subtraits such as insulin sensitivity (p=0.7), insulin
secretion (p=0.8) or the hyperbolic relation of both, the disposition index (p=0.7). In addition, no evidence for interaction
with BMI or sex was found. We subsequently performed a meta-analysis, additionally including the publicly available data
from the T2DM-subcohort of the WTCCC (n=4,855). The overall odds ratio within that meta-analysis was 0.96 (0.88–1.06).
Conclusions/Significance: There is no strong effect of the common genetic variation within the SOCS3 gene on the
development of T2DM.
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Introduction
The genetic impact on type 2 diabetes mellitus (T2DM) is well
known. However, due to various reasons, including considerable
heterogeneity of the disease, the identification of susceptibility genes
is difficult and most associations have not been replicated.
The suppressor of cytokine signalling 3 (SOCS3) provides a
molecular link between cytokine action and insulin signalling [1]. In
addition, SOCS3 has been shown to mediate a reduction of b-cell
volume and modulates cytokine signalling in pancreatic b-cells [2].
Thus, from a functional perspective, SOCS3 appeared to be a
convincing candidate gene with respect to T2DM. We investigated
the only tagging SNP A+930RG (rs4969168, noncoding) of the
gene [3] to examine its genetic impact on T2DM and parameters
of the glucose metabolism in three independent study populations;
one prospective case-cohort study and two cross-sectional study
populations. A meta-analysis including publicly available data was
also performed.
Results
We here investigated a potential association between the tagging
SNP A+930RG of the SOCS3 gene with T2DM or associated
subtraits in three independent study populations.
The replication rate of genotyping was 99% and the genotype
distribution were in Hardy Weinberg Equilibrium (x
2
EPIC=3.66;
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MeSyBePo=0.13; x
2
Leipzig=0.18). In all subsequent calculations
exclusively the dominant model was analysed due to the low
frequency of homozygous carriers of the. Cox proportional hazard
and logistic regression models adjusted for age, gender and BMI
did not show any significant associations between the polymor-
phism and T2DM (see table 1A–C). The association between the
polymorphism and validated indices estimating insulin sensitivity
was also investigated within the MesyBepo study population.
Comparably to the lack of association with diabetes, no relation to
insulin sensitivity (p=0.7), insulin secretion (p=0.8) or Disposition
Index was found (p=0.7) (see table 1D). In addition, no
interaction between the polymorphism with BMI or sex was
found with respect to T2DM.
We also performed a meta-analysis using the here genotyped
three study popualtions and publicly available data from the
WTCCC, resulting in a total 11,335 individuals. Crude odds ratios
were calculated for this meta-analysis due to limited access to
individualized information within the publicly available data. In
addition, the different study designs need to be considered for
interpretation of the meta-analysis. Crude OR was 0.95 (95%CI
0.77–1.17) for the EPIC-Potsdam cohort, 0.73 (95%CI 0.53–1.01)
for the MeSyBePo study population, 1.13 (95%CI 0.90–1.42) for
the population from the region of Leipzig and 0.96 (95%CI 0.85–
1.10) for the T2DM-subcohort in the WTCCC. Meta-analysis
revealed a total odds ratio of 0.96 (95%CI 0.88–1.06) (Figure 1).
Genotype frequencies of all study populations are shown in table 2.
Power calculations revealed that the meta-analysis provided 80%
power to detect a 12% risk modification.
Discussion
From a functional perspective, SOCS3 is a convincing
candidate gene for genetic association studies investigating
susceptibility for T2DM. This study examined a variant in the
39 UTR of SOCS3 for association with T2DM and related traits.
This variant covers the genetic variation within SOCS3 according
to HapMap data, thus being the only haplotype tagging SNP
within this gene [3]. The samples included a total of 1897
individuals from the cross-sectional MeSyBePo study, 1653
individuals from a cross-sectional study from the region of Leipzig
and 2957 individuals from the prospective EPIC-Potsdam study.
Surrogate measures of insulin secretion and sensitivity were
obtained in non-diabetic MeSyBePo participants. A meta-analysis
of the here genotyped data and publicly available data from the
WTCCC was additionally performed. This meta-analysis had an
80% power to detect effect sizes of 12% given the frequency of the
here investigated polymorphism. All results are negative for
association with T2DM or related traits.
Some shortcomings of this study should be mentioned. All high-
density genome-wide association studies have not found effects
within the region of SOCS3. Given the existing data the study may
be underpowered to demonstrate small associations, which are not
entirely unlikely given the existing results of genome-wide
association studies. Aiming to investigate those smaller effects the
here presented data may be valuable for future meta-analyses in
combination with additional future available data. The existing
data of genome-wide scans did not investigate potential interaction
with environmental factors such as BMI or sex. Those interactions
are unlikely to exist given our data. However, the analysis of
interactions further reduces the power of studies making future
meta-analyses also desirable.
In conclusion, we were unable to detect an effect of the one
tagging SNP A+930RG of the SOCS3-gene on T2DM or
associated subtraits. Although a substantial effect of this SNP can
be excluded, small risk modifications may still exist, which should
be investigated in future meta-analyses.
Materials and Methods
Details of recruitment and phenotyping (Case/Control: age
59.57/50.63 years; R 181/1088; = 144/484; BMI 32.24/28.67) of
the MeSyBePo-study were published recently [4]. In all partici-
pants of MeSyBePo a 75 g oral glucose tolerance test (OGTT)
with insulin measurements was performed. 325 participants with
T2DM were compared to 1,572 non-affected individuals. The
association between the polymorphism and the Disposition Index
was investigated only in individuals with NGT, IFG or IGT, since
accepted markers of insulin sensitivity and secretion have been
shown to be unreliable in patients with type 2 diabetes mellitus,
especially in patients with anti-diabetic treatment. An euglycemic
hyperinsulinemic clamp was performed in a subset of 56 healthy
controls. In these participants, the Insulin Sensitivity Index (ISI)
according to Stumvoll (ISI was calculated as: 0.157–4.576 10
25
Ins120– 0.00519 Gluc90 – 0.000299 Ins0) correlated best to the M-
value (r=0.591; p,0.001) of the clamps [5]. Therefore ISI was
subsequently used to estimate insulin sensitivity in the total cohort.
As the characteristics of our study population were basically
comparable to those of Stumvolls population, the ratio of
AUCInsulin/AUCGlucose, which performed best in Stumvolls study
compared to a hyperglycemic clamp, was used to estimate insulin
secretion. Correspondingly the disposition index (DI) was
calculated as the product of ISI and AUCInsulin/AUCGlucose [5,6].
A second cross-sectional study population was from the region
of Leipzig. DNA from 852 patients with T2DM (R 408, =444) and
Table 1. Results of the tagging SNP A+930RG (genetic
dominant model) for A) the Cox model for T2DM in EPIC, B)
the logistic regression model in MeSyBePo, C) the logistic
regression model in the Leipzig cohort and D) for the linear
regression model of D1) ISI-insulin sensitivity, D2) AUCInsulin/
AUCGlucose-insulin secretion, D3) DI-disposition index.
A)
Genotype (nsubcohort/nexternal
cases)
Hazard Ratio (95%CI) p-value
GG (1,835/563) 1 (reference)
GA+AA (399+32/118+10) 0.86 (0.66–1.13) 0.3
B)
Genotype (nnon-case/ncase) Odds Ratio (95%CI) p-value
GG (1227/268) 1 (reference)
GA+AA (322+23/55+2) 0.78 (0.54–1.12) 0.8
C)
Genotype (nnon-case/ncase) Odds Ratio (95%CI) p-value
GG (621/642) 1 (reference)
GA+AA (170+10/202+8) 1.25 (0.95–1.66) 0.1
D)
Genotype Mean (6SD) p-value
D1) GG 0.07960.027 0.7
GA+AA 0.07860.030
D2) GG 45.69630.17 0.8
GA+AA 46.02630.09
D3) GG 3.5361.81 0.7
GA+AA 3.4961.92
All models were adjusted for age, gender and BMI, respectively.
doi:10.1371/journal.pone.0003852.t001
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University Hospital in Leipzig, Germany were available for the
present study. The non-diabetic subjects had mean age 49614
years and mean BMI 28.665.6 kg/m
2, and patients with T2DM
had mean age 64611 years and mean BMI 29.665.2 kg/m
2
(arithmetic means6SD). In addition, OGTT was performed in all
non-diabetic subjects. Since impaired glucose tolerance is a T2DM
predicting factor, only subjects with normal glucose tolerance
(N=633) were included as healthy controls in the T2D case-
control study.
Association with incident T2DM was assessed in a nested case–
cohort study within the EPIC-Potsdam- (European Prospective
Investigation into Cancer and Nutrition) study, a prospective
cohort involving 27,548 Caucasian volunteers mainly aged 35–65
years from the general population [7]. The case-cohort has been
described in detail before [8]. 2,266 individuals were randomly
selected for a subcohort and 764 incident cases were included in
the present analysis. Because the subcohort is representative of the
entire cohort at baseline, 73 incident T2DM were included in the
subcohort and 691 incident cases were identified in the remaining
cohort, the latter classified as ‘external’ cases (external cases/
subcohort subjects: age 54.7/49.5 years; R 280/1,401, = 411/865;
BMI 30.4/26.0, mean follow up: 7 years). Both studies have been
approved by the local ethic authorities, namely the EPIC-study
was approved by the ethic committee of Brandenburg and
MeSyBePo was approved by the ethic committee of the University
of Potsdam and the Charite ´-Universita ¨tsmedizin Berlin. All study
participants gave written informed consent to the studies,
respectively.
Genotyping was performed by TaqManH-technology (HT7900
System; ABI, Foster City, CA, USA). Details of genotyping will be
given by the authors upon request. The polymorphism was chosen
by the tag SNP Picker on the International HapMap Project web
side with an r
2-cut off of 1 and a minor allel frequency cut off of
0.1 [3].
Finally publicly available data of a sub-cohort of the WTCCC
(Welcome Trust Case Control Consortium) with genotyped data
of the SOCS3 polymorphism were used including a total of 4,355
persons (ncase=1,.422; ncontrol=2,933).
Data were analyzed using SPSS (SPSS Inc., Chicago, IL, USA,
version 12.0) and SAS (SAS Institute, Cary, NC, USA, version
9.1). General linear model was calculated to analyse the effects of
the polymorphism on continuous variables after adjustment for
confounders (age, sex, BMI). Hazard ratios were calculated using
Cox proportional hazard regression analysis modified according to
the Barlow method in EPIC-Potsdam. Unconditional logistic
regression analysis was performed to estimate prevalent odds ratios
in MeSyBePo. Multiplicative interaction terms between the
Figure 1. Forest blot presenting the meta-analysis of the study populations EPIC, MeSyBePo, Leipzig and the WTCCC. The size of
each square is proportional to the study’s weight within the meta-analysis. The overall effect estimate is plotted as a diamond. The lateral points of
that diamond indicate the 95%-CI of this estimate.
doi:10.1371/journal.pone.0003852.g001
Table 2. Genotype frequency of the tagging SNP A+930RG in the three study populations included in the meta-analysis.
genotype study population (n %) total
EPIC MeSyBePo WTCCC Leipzig
cases AA 11 (1.4%) 2 (0.6%) 38 (2.0%) 8 (0.9%) 59 (1.5%)
AG 129 (16.8%) 56 (17.2%) 491 (25.6%) 202 (23.7%) 871 (22.7%)
GG 624 (81.8%) 267 (82,2%) 1,393 (72.4%) 642 (75.4%) 2,907 (75.8%)
Total 764 325 1,922 852 3,837
controls AA 31 (1.4%) 22 (1.4%) 71 (2.4%) 10 (1.3%) 134 (1.8%)
AG 388 (17.7%) 323 (20.6%) 758 (25.8%) 170 (21.2%) 1,638 (21.9%)
GG 1,774 (80.9%) 1,227 (78.0%) 2,104 (71.8%) 621 (77.5%) 5,726 (76.3%)
Total 2,193 1,572 2,933 801 7,498
doi:10.1371/journal.pone.0003852.t002
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potential interactions of these variables and disease risk. A two-
tailed alpha-error below 5% was considered to be significant.
Power analysis was performed using Quanto [9]. We assumed
an unmatched case-control design (EPIC 1:3.4, MeSyBePo 1:3.7,
Leipzig 1:0.94), a population risk of 0.06 for T2DM and
considered a two-sided p-value of 0.05. Meta-analysis has been
performed using the Mantel-Haenszel method, which assumes a
fixed effect and combines studies according to the weight given to
each study. All analyses were performed using a dominant genetic
model, due to the low frequency of homocygote mutant carriers.
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